ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 167

Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology

Maria Manara1, Carlo Alberto Scirè1, Marco A. Cimmino2, Marcello Govoni3, Fausto Salaffi4, Greta Carrara1, Carlomaurizio Montecucco5, Marco Matucci-Cerinic6, Giovanni Minisola7 and Kick-off of the Italina Network for Gout (KING) Study Group8, 1Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, 2Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, 3Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, 4Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, 5Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 6Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, 7Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, 8Italian Society for Rheumatology, SIR, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: gout, prognostic factors and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines recommend to maintain the serum uric acid (sUA) below the saturation point for monosodium urate (from 5 to 6.38 mg/dl). In this analysis we evaluated the influence of different sUA levels on the risk of acute attack in an observational setting.

Methods:

This is a longitudinal analysis of an ongoing multicentre cohort study including 450 patients with prevalent clinically diagnosed gout from 30 rheumatology centers across Italy (Kick-off of the Italian Network for Gout, KING, promoted by the Italian Society for Rheumatology – SIR; NCT01549210) recruited from June 2011 and January 2012. Participants were centrally selected from clinical registers by random sampling. All patients underwent full clinical evaluation at baseline, including general and disease-specific characteristics. During the first 6 months of follow-up the number of flares, sUA and concurrent treatment were collected.

The relationship between sUA and risk of flare was analyzed using logistic models on complete data, and estimation of the risk of flare is presented as odds ratios (OR) and 95% confidence intervals (CI). The optimal cut-off of sUA was explored by identifying the minimum cut-off associated with a significant increase of risk of flare.

Results:

A total of 178 patients were included in the analyses: 92.7% were male with a mean (SD) age of 64.5 (10.9) years, 22.9% had tophaceous and 18.7% polyarticular disease. Mean (SD) sUA was 6.1 (1.6) mg/dl, of which 26.9% <5mg/dl, 26.4% from 5-6mg/dl, 16.8% from 6-7mg/dl and 29.8 above 7mg/dl. During the follow-up of 6 months 60 patients (33.7%) presented at least one flare with a total of 140 flares.

SUA levels were linearly associated with an increased risk of flare: OR[95%CI] of 1.39 [1.13,1.71] per each mg/dl increase. The adjusted analyses confirmed a similar increase of risk of flare regardless of changes in urate-lowering therapy or prophylactic  treatment: OR 1.38 [1.12,1.71]. The minimum cut-off associated with a significant increase of risk of flare was 5.9 mg/dl with an OR of 1.90 [1.01,3.59]. Consistently, using sUA<5mg/dl as reference category, 5-6mg/dl was not associated with a significant increase of risk of flare (OR 1.54 [0.60, 4.15]) while 6-7mg/dl and >7mg/dl were associated with significant ORs: 2.90 [1.03,8.16] and 3.52 [1.43,8.62], respectively.

Conclusion:

The optimal management of gouty patients requires strict control of serum uric acid levels. A virtual absence of risk of flare is associated with levels of uric acid levels below 4mg/dl, but the operative cut-off of 6mg/dl is a robust limit to discriminate patients with increased risk of relapse.

sua.png


Disclosure:

M. Manara,
None;

C. A. Scirè,
None;

M. A. Cimmino,
None;

M. Govoni,
None;

F. Salaffi,
None;

G. Carrara,
None;

C. Montecucco,
None;

M. Matucci-Cerinic,
None;

G. Minisola,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-uric-acid-control-and-risk-of-flare-according-to-different-cut-offs-in-patients-with-gout-longitudinal-analysis-from-the-king-study-of-the-italian-society-for-rheumatology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology